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RIMARY CNS lymphomas account for less than 2% 
of all intracranial neoplasms.9 By definition, these tu-
mors are extranodal and arise primarily in the cra-
niospinal axis; they should not be confused with systemic
lymphomas that secondarily metastasize to the CNS. Even
more rare are PPLs. In one study the incidence of pituitary
lymphoma among a large cohort of patients who underwent
transsphenoidal surgery for sellar masses was noted to be
less than 1%.10 During the past two decades, the number of
cases of PPLs reported has increased.11 Most PPLs are of B-
cell origin on histopathological examination, although there
are a few cases of PPLs of T-cell origin. 
Extranodal NK/T-cell lymphomas are distinct pathologi-
cal entities from B- or T-cell lymphomas; they have a high-
ly aggressive course with poor prognosis. Although gener-
ally rare, these tumors are more common in people of Asian,
Mexican, and South American descent. The lesions have a
strong association with EBV. Histologically, the most com-
mon immunophenotype is CD2-positive, surface CD3-neg-
ative, cytoplasmic CD3-positive, and CD56-positive. Extra-
nodal NK/T-cell lymphomas often affect the nasal cavity
and other mucosal sites of the upper gastrointestinal tract.
They frequently present in midline facial structures as nasal
obstruction or midfacial destruction. Some cases of NK/
T-cell lymphomas involving the CNS via direct extension
from the nose have been reported, as has one case of prima-
ry brain NK/T-cell lymphoma;15 however, no primary NK/
T-cell lymphomas arising from the pituitary gland have been
reported previously. To the best of our knowledge, we report
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 Primary pituitary lymphomas (PPLs) are rare tumors of the central nervous system, and most are of B-cell origin.
Extranodal NK/T-cell lymphomas are uncommon neoplasms that are highly aggressive and show a strong association
with Epstein–Barr virus. They most commonly affect the nasal cavity and paranasal sinuses; manifestation as a pri-
mary pituitary tumor has never been described. The authors report a case of NK/T-cell lymphoma of the pituitary gland
and review 17 cases of PPL from the literature.
All patients had been evaluated at presentation for clinical, neuroimaging, and histopathological findings. Patients
who had systemic lymphoma with secondary involvement of the pituitary gland were excluded. The mean patient age
was 55.5 years (range 26–86 years); the male/female ratio was 13:5. The most common presentation was pituitary in-
sufficiency (72%), followed by headache (56%), diplopia (39%), visual loss (28%), and fever (22%). Thirteen patients
(72%) exhibited anterior hypopituitarism and seven (39%) had diabetes insipidus at presentation. Magnetic resonance
imaging demonstrated enhancing parasellar masses with diffuse enlargement of the pituitary gland (94%), suprasellar
extension (44%), cavernous sinus extension (39%), and stalk thickening (22%). Thirteen patients (72%) had B-cell
lymphoma, four (22%) had T-cell lymphoma, and one (6%) had NK/T-cell lymphoma.
Primary pituitary lymphomas are rare entities with a range of clinical presentations and neuroimaging findings that
are unique from those of patients who present with pituitary adenomas. The pathological entity of NK/T-cell lympho-
ma is distinct, and its course is very aggressive with a poor prognosis. (DOI: 10.3171/JNS-07/09/0660)
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the first case of extranodal NK/T-cell lymphoma presenting
as a PPL. We present this unique case and also review 17
other cases of PPL found in the literature. The clinical pre-
sentation, neuroimaging characteristics, and histopatholog-
ical features are discussed. We excluded patients who had
systemic lymphoma with secondary involvement of the pi-
tuitary gland.
Case Report
History and Examination. This 26-year-old Hispanic man
presented with a 2-week history of headaches associated
with nausea and vomiting, which was then followed by
worsening diplopia. On examination, the patient had a mild
left sixth cranial nerve palsy. The remainder of his exami-
nation revealed normal findings.
A CT scan of the head without contrast revealed a hyper-
dense mass in the sellar and suprasellar region extending to
the left side of the sella and cavernous sinus (Fig. 1). Mag-
netic resonance imaging of the brain (Fig. 2) demonstrated
an enhancing sellar mass with suprasellar extension com-
pressing the optic chiasm. The mass also involved the pla-
num sphenoidale, anterior clinoid process, infundibulum,
and clivus. There was also extension into bilateral cavern-
ous sinuses with encasement of the cavernous carotid arter-
ies bilaterally. There was dural enhancement adjacent to the
anterior skull base, planum sphenoidale, and clivus. 
A formal ophthalmological examination verified an in-
complete left sixth cranial nerve palsy. An endocrinological
evaluation revealed hypocortisolism, hypothyroidism, and
hypotestosteronemia. The patient’s serum prolactin level
was slightly elevated at 22 ng/ml, consistent with stalk ef-
fect. Corticosteroid and thyroid hormone replacement was
initiated to treat his hypopituitarism. The patient’s erythro-
cyte sedimentation rate was elevated at 27 mm/hour, and he
had fevers during his hospital course without any positive
blood or cerebrospinal fluid cultures. A lymphoma of the
pituitary gland was suspected, and a transnasal transsphe-
noidal biopsy of the mass was performed. 
Operation. At surgery, tumor was seen at both sphenoid
ostia. The face of the sphenoid sinus was opened widely,
and the tumor within the sphenoid sinus was removed. Re-
sults of the initial preliminary frozen section revealed lym-
phoma. After removing the tumor in the sphenoid sinus, the
sellar floor was incompetent and the sellar dura mater was
opened. The mass in the sella appeared abnormal and a bi-
opsy specimen was obtained. No further resection was per-
formed because of the preliminary diagnosis of lymphoma.
Pathological Examination. Histological examination of
both biopsy samples from the sphenoid and sella revealed a
diffusely infiltrative mass involving the sphenoid sinus mu-
cosa and pituitary gland (Fig. 3). The infiltrative cells were
small- to medium-sized lymphocytes that were immuno-
positive for CD45 (leukocyte common antigen). Apoptotic
cells were numerous, and occasional mitotic figures were
also present. Angiocentric growth was not seen. Immuno-
histochemical staining showed the tumor cells to be nega-
tive for the B-cell marker CD20 and immunoreactive for the
T-cell marker CD3 but in a cytoplasmic rather than surface
pattern. Further marker studies showed the tumor cells to be
positive for CD2 and CD56, indicating that this was an ex-
tranodal, nasal-type NK/T-cell lymphoma. Markers CD4,
CD5, CD7, CD8, CD79a, CD30, TdT, and AE1/AE3 (pan-
cytokeratin) were negative. The tumor cells were also found
to be strongly positive for EBERs.
Postoperative Course. Postoperatively, the patient re-
mained stable, although he had transient diabetes insipidus,
which resolved by the time of discharge from the hospital.
The remainder of the hospital course was uneventful. The
results of an HIV test were negative. Further metastatic
workup included CT scans of the chest, abdomen, and pel-
vis, which did not reveal any masses. Bone marrow aspir-
ation was negative for any evidence of malignancy. Isolated
disease of the pituitary gland was diagnosed, and the patient
was started on postoperative adjuvant radiation and chemo-
therapy.
The patient underwent fractionated intensity-modulated
radiation therapy to the tumor site (25 fractions of 200 cGy
for a total dose of 5000 cGy) followed by six cycles of hy-
per-CVAD chemotherapy (cyclophosphamide, vincristine,
doxorubicin, and dexamethasone) with intrathecal metho-
trexate and cytarabine. Follow-up MR imaging (Fig. 4) per-
formed 5 months after surgery demonstrated a significant
interval decrease in the size of the suprasellar and skull base
mass, suggestive of a response to treatment. There was still
residual enhancement seen in the left cavernous sinus and
Meckel cave; however, a screening bone marrow biopsy
demonstrated bone marrow invasion of NK/T-cell lym-
phoma. The patient was readmitted to undergo additional
chemotherapy (cisplatin, etoposide, gemcitabine, methyl-
prednisolone sodium succinate injection, and intrathecal cy-
tarabine liposome). Four weeks later, the patient developed
neutropenic fever and overwhelming infections and was
found to have widespread dissemination of lymphoma to his
liver. Given his poor prognosis, the patient was transferred
to hospice care where he eventually died of the lymphoma.
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FIG. 1. A CT image of the head demonstrating a hyperdense
mass in the sellar and suprasellar region extending to the left side of
the sella.
Results
From a survey of the literature, we identified 17 addition-
al cases of PPL for a total review of 18 cases (Table 1). The
mean age of patients was 55.5 years (range 26–86 years),
and there was a 13:5 male/female ratio. The most common
presentation was pituitary insufficiency (72%), followed by
headache (56%), diplopia (39%), visual loss (28%), and
fever (22%). Thirteen patients (72%) exhibited anterior hy-
popituitarism and seven (39%) had diabetes insipidus at pre-
sentation. Four (22%) had mild hyperprolactinemia from
stalk compression effect. The MR images demonstrated en-
hancing parasellar masses with diffuse enlargement of the
pituitary gland (94%), suprasellar extension (44%), caver-
nous sinus extension (39%), and stalk thickening (22%).
Thirteen patients (72%) had B-cell lymphoma, four (22%)




Primary CNS lymphomas constitute approximately less
than 2% of all intracranial neoplasms.8 Although these tu-
mors have been known to be associated with immunocom-
promised conditions and AIDS, recent data have shown a
significant increase in the incidence with immunocompe-
tent patients.7,8,28 The incidence of PPL is very low; PPL was
encountered in one (✱ 1%) of 1120 patients who underwent
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FIG. 2. Coronal (A–C) and sagittal (D) Gd-enhanced T1-weighted
and coronal T2-weighted (E) MR images of the brain demonstrating an
enhancing sellar mass with suprasellar extension compressing the optic
chiasm. The mass also involves the planum sphenoidale, anterior clinoid
process, infundibulum, and clivus. There is also extension into bilateral
cavernous sinuses with encasement of the cavernous carotid arteries
bilaterally. There is dural enhancement adjacent to the anterior skull base
(C, arrows), planum sphenoidale, and clivus.
FIG. 3. Photomicrographs. Left: Examination of the pituitary mass stain demonstrating lymphoma cells infiltrating
and effacing the pituitary gland. The larger cells with noticeable eosinophilic cytoplasm are entrapped anterior pituitary
cells. H & E. Right: In situ hybridization for EBV–EBER. The tumor cells are strongly positive (blue nuclear staining),
whereas the overlying epithelium and submucosal blood vessels are negative. Original magnification ✸ 400 (left) and ✸
200 (right).
transsphenoidal resection for pituitary masses.10 The num-
ber of cases of primary lymphomas presenting as pituitary
tumors reported in the literature seems to be increasing in
recent years.10
In our review of 18 patients with PPL, we found that the
mean age at presentation and male predominance were sim-
ilar to those described in patients with primary CNS lym-
phomas. Patients in immunodeficient states and with PPL
presented at a younger age. Endocrine abnormalities were
strongly associated with PPL, and pituitary insufficiency
was the most common presentation. Seventy-two percent
of patients exhibited anterior hypopituitarism and 39% had
diabetes insipidus, which may result from involvement or
compression of the pituitary stalk, hypothalamus, or para-
ventricular region of the third ventricle. The variety of endo-
crine abnormalities suggests different origins of lymphopro-
liferative tissue.11 Clinically, patients with hypopituitarism
presented with a variety of symptoms, including fatigue,
muscle weakness, loss of libido, amenorrhea, thirst, and
polyuria. 
Headache was also a common presenting symptom
(56%). Diplopia due to cavernous sinus compression of the
cranial nerves was present in 39% of patients and visual
field or acuity compromise was present in 28%. One pa-
tient had facial numbness in the first and second divisions
of the trigeminal nerve and one patient had sensorineural
hearing loss. Four patients (22%), including ours, present-
ed with a fever of unknown origin. 
Nonfunctioning pituitary adenomas typically appear with
visual field and acuity compromise, signs of hypopituitar-
ism, and nonspecific headaches. Although PPLs may pre-
sent with similar symptoms, the presence of diabetes insip-
idus, cranial neuropathies resulting in diplopia, and fever 
of unknown origin should raise the suspicion of a nonade-
nomatous sellar/parasellar lesion, such as a lymphoma.11 As
many as 25% of patients with nonadenomatous sellar/para-
sellar lesions have impairment of the second, third, fourth,
and sixth cranial nerves.10
The MR images demonstrated enhancing parasellar
masses with diffuse enlargement of the pituitary (94%),
suprasellar extension (44%), cavernous sinus extension
(39%), and stalk thickening (22%). The MR images ob-
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FIG. 4. Follow-up MR images obtained 5 months after surgery,
chemotherapy, and radiation therapy, demonstrating significant in-
terval decrease in size of the parasellar mass suggesting response to
treatment. Residual enhancement is seen in the left cavernous sinus.
TABLE 1
Clinical summary of 18 patients with PPL*
Age (yrs), Endocrine
Authors & Year Sex Clinical Presentation Abnormality Coexisting Lesion Origin
Singh et al., 1993 28, M HA, visual loss, facial numbness –– –– B-cell
Samuels & de la Monte, 49, M HA, SNHL, nystagmus, decreased libido ant hypopit, DI, PRL –– B-cell
1994
Gottfredsson et al., 1996 48, M HA, nausea/vomiting, meningismus,  –– –– B-cell
fever, diplopia (CN VI palsy)
Shaw et al., 1997 73, F HA, fatigue, diplopia (CN VI palsy), ant hypopit, DI, PRL –– B-cell
polyuria
Li et al., 1998 77, M generalized weakness ant hypopit –– B-cell
Sakakibara et al., 1998 53, M HA, diplopia (CN VI palsy) –– –– T-cell
Freda & Post, 1999 48, M HA, diplopia (CN III, VI palsies) –– –– B-cell
Kuhn et al., 1999 67, F diplopia (CN III palsy), visual loss ant hypopit pituitary adenoma T-cell
Au et al., 2000 83, M HA, visual loss ant hypopit, DI pituitary adenoma B-cell
Mathiasen et al., 2000 65, M muscle weakness, fatigue, decreased ant hypopit, PRL lymphocytic hypo- B-cell
libido physitis
Singh et al., 2000 44, M HA, visual loss, blurry vision, de- –– lymphocytic hypo- B-cell
creased libido physitis
Spina et al., 2000 52, F HA, diplopia (CN VI palsy) ant hypopit, DI lymphocytic hypo- T-cell
physitis
Landman et al., 2001 86, F fever, chills, weight loss ant hypopit, DI –– B-cell
Silfen et al., 2001 15, M polyuria, polydipsia, weight loss ant hypopit, DI –– B-cell
Kaufmann et al., 2002 74, M visual loss, mental status change, ant hypopit –– B-cell
generalized weakness, weight loss
Katz et al., 2003 64, F nausea/vomiting, diarrhea, peripheral ant hypopit, DI –– B-cell
& periorbital edema
Huang et al., 2005 47, M fever, chills, decreased libido ant hypopit lymphocytic hypo- T-cell
physitis
present study 26, M HA, diplopia (CN VI palsy), fever ant hypopit, PRL –– NK/T-cell
* ant hypopit = anterior hypopituitarism; CN = cranial nerve; DI = diabetes insipidus; HA = headache; PRL = hyperprolactinemia;
SNHL = sensorineural hearing loss; –– = none.
tained in the patient in our case showed stalk thickening and
enhancement as well as dural enhancement in the anterior
skull base and clivus, which are not typical imaging charac-
teristics of pituitary adenomas, thereby suggesting a non-
adenomatous lesion. Lymphomas usually appear iso- to hy-
perdense on CT imaging. On MR imaging, they are usually
isointense on T1-weighted images and iso- to hypointense
on T2-weighted images.17,20 They also usually show diffu-
sion restriction (hyperintense on diffusion weighted images
and hypointense on the apparent diffusion coefficient map),
which reflects the hypercellular density of these tumors.
Lymphomas almost always enhance homogeneously after
Gd administration.5
Four patients had histological evidence of lymphocytic
hypophysitis and two patients had underlying pituitary ade-
nomas. Although the exact mechanism of pathogenesis of
PPL remains unknown, some have postulated that lympho-
cytic hypophysitis and pituitary adenomas may be risk fac-
tors for acquiring pituitary lymphomas.11,13 One hypothesis
is that a polyclonal population of inflammatory lympho-
cytes may undergo monoclonal expansion possibly trig-
gered by an infectious agent. This may be analogous to the
phenomenon seen in Hashimoto thyroiditis as a risk factor
for developing thyroid lymphomas.1 As for underlying pitu-
itary adenomas, their role in the pathogenesis of PPL is un-
clear. Some authors have postulated that the combination of
monoclonal expansion of lymphocytic infiltrates, expres-
sion of adenoma-specific signaling or adhesion molecules
that attract circulating lymphocytes, and the mitogenic po-
tential of some pituitary hormones may contribute to lym-
phoma growth within a pituitary adenoma.11 In the present
case, there was no evidence for a preexisting pituitary ade-
noma.
The majority of primary CNS tumors (98%) are mono-
clonal B-cell non-Hodgkin lymphomas.20 Histologically,
lymphomas of the pituitary gland resemble those of the
CNS. Similar to primary CNS lymphomas, most are pre-
dominantly B-cell non-Hodgkin lymphoma. In our review
of 18 patients with PPL, 13 (72%) were B-cell immunophe-
notype, four (22%) were T-cell immunophenotype, and one
(6%) was NK/T-cell immunophenotype. 
Extranodal NK/T-Cell Lymphoma
Extranodal NK/T-cell lymphomas are a rare group of
invasive and destructive lymphoproliferative disorders that
are immunophenotypically distinct from B-cell and T-cell
non-Hodgkin lymphomas. They are derived from either ac-
tivated NK cells or, rarely, cytotoxic T-cells. This tumor has
been recently recognized as a distinct entity within the
World Health Organization classification of hematopoietic
and lymphoid neoplasms.4 The NK/T-cell lymphomas were
previously known as lethal midline granuloma, polymor-
phic reticulosis, or angiocentric lymphoma. The incidence
of these tumors is higher in Asia, Mexico, and South Amer-
ica.14,24 Within the US, NK/T-cell lymphomas comprise 1 to
2% of non-Hodgkin lymphomas.22 These lymphomas are
commonly extranodal and usually arise within the nasal
cavity as midfacial destructive lesions and present with na-
sal obstruction, facial pain, or swelling. Other extranasal
sites of involvement, including the pharynx, gastrointestinal
tract, and testis, have been described; tumors in these loca-
tions are also referred to as “nasal-type.” Metastasis to the
CNS from nasal NK/T-cell lymphomas has been reported in
less than 3% of cases;22 there has been one case reported of
primary brain NK/T-cell lymphoma.15 To our knowledge,
primary pituitary NK/T-cell lymphoma has not been previ-
ously reported. We report the first case of a nasal-type NK/
T-cell lymphoma arising primarily in the pituitary gland
with the classic immunophenotype. 
Histologically, NK/T-cell lymphomas are often angio-
centric with prominent necrosis and vascular destruction.
Immunophenotypically, they typically express CD2 (T-cell
marker), CD56 (NK cell marker), and intracellular cyto-
plasmic CD3 but lack surface CD3 expression. Other pos-
itive markers include cytotoxic granule proteins, granzyme
B, TIA-1, and perforin.15 Another distinguishing feature of
NK/T-cell lymphomas is the strong association with EBV,
with EBER positivity in greater than 80% of cases.22
Most cases of NK/T-cell lymphoma are aggressive and
are associated with an unfavorable clinical outcome. Given
the rarity of this disease, the optimal therapy has not been
clearly defined. Treatment of nasal NK/T-cell lymphoma
has consisted of radiotherapy, with or without multiagent
chemotherapy;6 however, no effective treatment regimen
has been yet elucidated, and this malignancy manifests an
aggressive course. The highly aggressive course with poor
response and short survival with standard therapies has led
some investigators to recommend consolidation with bone
marrow or peripheral stem cell transplantation.3
Ko et al.18 found that CD56-positive EBV-negative lym-
phomas at extranasal sites were clinically less aggressive
and exhibited less necrosis than CD56-postive EBV-pos-
itive NK/T-cell lymphomas. The median survival time of
all 47 patients in their series was 14 months, with a 2-year
survival rate of 40%. The results of another study of 42
patients with nasal-type extranodal NK/T-cell lymphoma
demonstrated a mean survival time of 30 months. In that
study, younger female patients appeared to have longer sur-
vival times.24 Unfortunately, systemic progression of this
disease is common and, despite radiation therapy, surgery,
and chemotherapy, poor outcomes prevail and death can
occur within a year of diagnosis.22 In summary, NK/T-cell
lymphoma is an aggressive tumor with a distinctive clin-
icopathological profile and an unfavorable clinical course,
and, as demonstrated in the present report, it may rarely
present as a pituitary mass. 
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